A promising next research task would be to target inflammatory cytokines via a blockade of the JAK-signaling transducer and transcriptional activator (STAT) and TIM-1 signaling pathways, in order to better target the development and survival of autoreactive pathogenic plasma cells during the early stages of SLE. The gene discussed is HAVCR1; the disease is systemic lupus erythematosus.